Phase, Inc., founded in 2020, has positioned itself at the intersection of biotechnology, medical devices, VR/AR, and 3D printing industries. With the slogan "3D printing for bioinnovation.", the company has developed a proprietary platform that uniquely enables PDMS and other biocompatible materials to be 3D printed for commercial applications, offering a resolution that was previously considered unattainable.
The startup recently received a substantial investment of $1.80M in the form of a grant on February 22, 2024, from a reputable source—the National Institutes of Health. This funding highlights the endorsement of Phase's technological potential and its perceived value in advancing modern medical practices.
Headquartered in the United States, Phase, Inc. is poised to make significant strides in bioengineering, leveraging its innovative platform to tap into various growth markets and drive transformative healthcare solutions.